Phil Southerland is the CEO and Co-Founder of Supersapiens. In 2019, Supersapiens approached Abbott about bringing their technology to the athletic community, and a partnership was soon  established. In September 2020, Abbott announced that its Libre Sense Glucose Sport Biosensor had achieved a CE Mark. It is the first  CGM approved for non-diabetic use in the world. By combining Abbott's proven track record in glucose sensing technology along with  Supersapiens' app and personalized analytics, athletes are able to better understand the correlation between their glucose levels and their athletic performance.